中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

111 records (took 0.018 seconds)

    광학영상 조영제, 그 용도 및 장치
    71.
    发明申请
    광학영상 조영제, 그 용도 및 장치 审中-公开
    光学成像对比剂，其使用及其设备

    公开(公告)号：WO2011049405A2

    公开(公告)日：2011-04-28

    申请号：PCT/KR2010/007287

    申请日：2010-10-22

    Applicant: 경북대학교 산학협력단 ,  유정수 ,  박정찬

    Inventor： 유정수 ,  박정찬

    IPC: A61K51/00 ,  A61P35/00 ,  A61K103/30 ,  A61K101/00

    CPC classification number: G01T1/164 ,  A61K49/0002 ,  A61K49/0067 ,  A61K49/1857 ,  A61K51/02 ,  A61K51/025 ,  A61K51/0491 ,  A61K51/1051 ,  A61K51/1244 ,  G01T7/08

    Abstract: 본 발명은 광학영상 조영제, 그 용도 및 장치에 관한 것이다. 본 발명의 광학영상 조영제는 발광을 위하여 별도의 형광물질 또는 발광물질 을 포함할 필요가 없어 원래 분자의 물리화학적 성질을 변화시키지 않고도 광학영 상을 획득할 수 있다. 본 발명의 광학영상 조영제는 많은 경우 광학/핵의학 이중영 상 조영제로 사용될 수 있으며, 방사성치료와 동시에 치료효과를 광학영상으로 모 니터링할 수 있는 장점을 가지고 있다. 또한, 형광물질과 결합되는 경우 외부에서 에너지가 유입되지 않고서도 광학영상 조영제에서 발생하는 에너지를 통해 자체적 으로 형광물질에서 빛이 방출되어 광량을 증가시키고 조직 투과력을 향상시킬 수 있다.

    Abstract translation: 本发明涉及光学成像造影剂，其用途及其装置。 本发明的光学成像造影剂不需要包含发出光的单独的荧光材料或发光材料，因此可以在不改变原始分子的物理化学性质的情况下获得光学图像。 本发明的光学成像造影剂在许多情况下可以用作光学/核医学双成像造影剂，并且能够与放射治疗同时从光学图像监测治疗效果。 此外，当与荧光材料连接时，本发明的光学成像造影剂可以从光学造影剂独立产生的能量从荧光材料发光，而不会从外部提供能量，因此允许光量 以增加组织渗透性。

    BIOCHEMICAL METHODS FOR MEASURING METABOLIC FITNESS OF TISSUES OR WHOLE ORGANISMS
    72.
    发明申请
    BIOCHEMICAL METHODS FOR MEASURING METABOLIC FITNESS OF TISSUES OR WHOLE ORGANISMS 审中-公开
    用于测量组织或全身代谢适应性的生物化学方法

    公开(公告)号：WO2008134662A1

    公开(公告)日：2008-11-06

    申请号：PCT/US2008/061819

    申请日：2008-04-28

    Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA ,  HELLERSTEIN, Marc, K.

    Inventor： HELLERSTEIN, Marc, K.

    IPC: A61K51/00 ,  A61M36/14 ,  G01N33/574

    CPC classification number: A61K51/02 ,  A61K49/0004 ,  C12Q1/6883 ,  C12Q2600/136 ,  C12Q2600/158

    Abstract: The present invention relates to biochemical methods for assessing metabolic fitness and/or aerobic demands of a living system. Specifically, the rate of synthesis and turnover of the molecular components of mitochondrial mass are used to determine the aerobic capacity and/or aerobic demand of tissues or living organisms. The direct measurement of metabolic fitness and/or aerobic demand by this means can be used as an index of the efficacy of an exercise training program or other therapeutic intervention; as a medical risk factor for predicting the risk of cardiovascular disease, diabetes, death or other health outcome; or as an aid to pharmaceutical companies for drug discovery in the area of metabolic fitness, deconditioning, and oxidative biology.

    Abstract translation: 本发明涉及用于评估生活系统的代谢适应性和/或需氧需求的生物化学方法。 具体来说，线粒体质量分子成分的合成率和周转率用于确定组织或活体的有氧能力和/或有氧需求。 通过这种方式直接测量代谢适应度和/或有氧需求可以用作运动训练计划或其他治疗干预的功效的指标; 作为预测心血管疾病，糖尿病，死亡或其他健康结果风险的医疗风险因素; 或协助制药公司在代谢适应性，脱色和氧化生物学领域进行药物发现。

    SYSTEM AND METHOD FOR AN AUTOMATED SYNTHESIS OF GALLIUM-68 GENERATOR-BASED RADIOPHARMACEUTICAL AGENTS
    76.
    发明申请
    SYSTEM AND METHOD FOR AN AUTOMATED SYNTHESIS OF GALLIUM-68 GENERATOR-BASED RADIOPHARMACEUTICAL AGENTS 审中-公开
    基于GALLIUM-68发生器的放射性核素的自动合成系统和方法

    公开(公告)号：WO2005123144A3

    公开(公告)日：2006-08-03

    申请号：PCT/US2005002063

    申请日：2005-01-19

    Applicant: UNIV TEXAS ,  CHAO K S CLIFFORD ,  YANG DAVID J ,  MOURTADA FIRAS

    Inventor： CHAO K S CLIFFORD ,  YANG DAVID J ,  MOURTADA FIRAS

    IPC: A61K51/00 ,  A61K51/02 ,  A61M36/14 ,  C07F5/00

    CPC classification number: A61K51/02

    Abstract: Systems and methods are described for efficiently producing a radiopharmaceutical agent. The system includes a generator that provides an admixture comprising hydrochloric acid and gallium-68 (Ga-68). A heater initiates a removal process by evaporating the hydrochloric acid from the admixture resulting in a substantially purified Ga-68. A plurality of valves provides a buffer and a prodrug that gets mixed with the Ga-68 to produce Ga-68 radiopharmaceutical agent.. Additionally, the valves may provide water or a transchelator to the Ga-68 radiopharmaceutical agent to optimize the yield. A method includes providing an admixture comprising hydrochloric acid and Ga-68. The method also includes removing the hydrochloric acid by heating the admixture and subsequently evaporating the hydrochloric acid, resulting in a substantially purified Ga-68. The method further includes adding a buffer and a prodrug to the substantially purified Ga-68 to produce the Ga-68 radiopharmaceutical agent.

    Abstract translation: 描述了用于有效地生产放射性药剂的系统和方法。 该系统包括提供包含盐酸和镓-68（Ga-68）的混合物的发生器。 加热器通过从混合物中蒸发盐酸来引发去除过程，导致基本上纯化的Ga-68。 多个阀提供缓冲液和前药，其与Ga-68混合以产生Ga-68放射性药物。另外，阀可以向Ga-68放射性药剂提供水或转运器以优化产率。 一种方法包括提供包含盐酸和Ga-68的混合物。 该方法还包括通过加热混合物并随后蒸发盐酸除去盐酸，得到基本纯化的Ga-68。 该方法还包括向基本纯化的Ga-68中加入缓冲液和前药以制备Ga-68放射性药剂。

    COMBINATION OF GALLIUM COMPOUNDS WITH NONCHEMOTHERAPEUTIC ANTICANCER AGENTS IN THE TREATMENT OF NEOPLASIA
    77.
    发明申请
    COMBINATION OF GALLIUM COMPOUNDS WITH NONCHEMOTHERAPEUTIC ANTICANCER AGENTS IN THE TREATMENT OF NEOPLASIA 审中-公开
    凝胶化合物与非化学治疗药物在治疗神经细胞中的组合

    公开(公告)号：WO2004060317A3

    公开(公告)日：2005-12-22

    申请号：PCT/US0341746

    申请日：2003-12-31

    Applicant: GENTA INC ,  WARRELL RAYMOND P JR ,  GRANT STEFAN C ,  BROWN BOB D

    Inventor： WARRELL RAYMOND P JR ,  GRANT STEFAN C ,  BROWN BOB D

    IPC: A61K20060101 ,  A61K33/24 ,  A61K39/395 ,  A61K45/06 ,  A61K51/02

    CPC classification number: A61K51/02 ,  A61K33/24 ,  A61K39/395 ,  A61K45/06 ,  A61K2300/00

    Abstract: The present invention relates to a combination of a pharmaceutical composition comprising a gallium compound, especially gallium nitrate, and one or more nonchemotherapeutic anticancer agents (NCAA) including antibodies, antisense molecules, anti-telomerase agents, aptamers, biologic response modifiers, bisphosphonates, cytotoxic fusion proteins, immunomodulatory agents, immunostimulatory agents, molecular decoys, molecular inhibitors, proteasome inhibitors, protein kinase inhibitors, retinoids, transcription factors and arsenic compounds, for the treatment of neoplasic disease in a mammal in need of treatment thereof.

    Abstract translation: 本发明涉及包含镓化合物，特别是硝酸镓的药物组合物和一种或多种非化学治疗性抗癌剂（NCAA）的组合，包括抗体，反义分子，抗端粒酶试剂，适体，生物反应调节剂，双膦酸盐，细胞毒性 融合蛋白，免疫调节剂，免疫刺激剂，分子诱饵，分子抑制剂，蛋白酶体抑制剂，蛋白激酶抑制剂，类维生素A，转录因子和砷化合物，用于治疗需要治疗的哺乳动物中的新生儿疾病。

    MICROSPHERES COMPRISING THERAPEUTIC AND DIAGNOSTIC RADIOACTIVE ISOTOPES
    79.
    发明申请
    MICROSPHERES COMPRISING THERAPEUTIC AND DIAGNOSTIC RADIOACTIVE ISOTOPES 审中-公开
    包含治疗和诊断放射性同种异体的微环境

    公开(公告)号：WO2005035005A1

    公开(公告)日：2005-04-21

    申请号：PCT/US2004/007061

    申请日：2004-03-08

    Applicant: BIOSPHERE MEDICAL ,  SCHWARZ, Alexander ,  KROM, James, A.

    Inventor： SCHWARZ, Alexander ,  KROM, James, A.

    IPC: A61K51/00

    CPC classification number: A61K51/02 ,  A61K51/1251

    Abstract: One aspect of the present invention relates to a microsphere impregnated with a radioisotope that emits therapeutic ß-particles and a radioisotope that emits diagnostic γ-radiation; wherein the atomic number of the first radioisotope is not the same as the atomic number of the second radioisotope. In one preferred embodiment, the microsphere is composed of glass impregnated with 90 Y as the source of the therapeutic ß-emissions and 198 Au as the source of the diagnostic γ-emissions. Another aspect of the present invention relates to the preparation of a microsphere impregnated with a radioisotope that emits therapeutic ß-particles and a radioisotope that emits diagnostic γ-radiation; wherein the atomic number of the first radioisotope is not the same as the atomic number of the second radioisotope. In one preferred embodiment, a glass microsphere containing 90 Y and 198 Au is prepared by neutron activation of a glass microsphere comprising glass, 89 Y and 197 Au. Another aspect of the present invention relates to administration to a mammal of a therapeutically effective amount of microspheres impregnated with a ß-emitting radioisotope and a γ-emitting radioisotope; wherein the atomic number of the first radioisotope is not the same as the atomic number of the second radioisotope. In one preferred embodiment, said microspheres are administered to the patient through a catheter.

    Abstract translation: 本发明的一个方面涉及一种用放射性同位素浸渍的微球，其发射治疗性β颗粒和发射诊断性γ-辐射的放射性同位素; 其中第一放射性同位素的原子序号与第二放射性同位素的原子序号不同。 在一个优选实施方案中，微球由浸渍有作为治疗性β发射源和<198> Au作为诊断性γ发射源的<90> Y的玻璃浸渍。 本发明的另一方面涉及一种用放射性同位素浸渍的微球的制备方法，所述放射性同位素发射治疗性β颗粒和发射诊断性γ-辐射的放射性同位素; 其中第一放射性同位素的原子序号与第二放射性同位素的原子序号不同。 在一个优选的实施方案中，通过中和活化玻璃微珠制备含90°和190°Au的玻璃微球，所述玻璃微球包括<89> Y和 Au。 本发明的另一方面涉及向哺乳动物施用浸渍有β发射放射性同位素和γ发射放射性同位素的治疗有效量的微球体; 其中第一放射性同位素的原子序号与第二放射性同位素的原子序号不同。 在一个优选的实施方案中，所述微球通过导管施用于患者。

Patent Agency Ranking